Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Syncona Shs GBP ( (GB:SYNC) ) has shared an update.
Achilles Therapeutics plc, an investment of Syncona Limited, announced plans for a members’ solvent voluntary liquidation to return capital to shareholders. The estimated return to ordinary shareholders is between £1.20 to £1.32 per share. Syncona holds 11,086,909 shares in Achilles, with its holding valued at £8.5 million as of September 2024. This move is expected to affect Syncona’s portfolio value and may influence stakeholders’ perceptions of its investment strategy.
More about Syncona Shs GBP
Syncona Limited is a life science investor focused on creating, building, and scaling a portfolio of global leaders in life sciences. The company aims to develop transformative treatments by partnering with academic founders and experienced management, targeting areas with high unmet needs. Syncona maintains a diversified portfolio of 20-25 leading life science businesses, focusing on delivering patient impact and long-term returns to shareholders.
YTD Price Performance: -14.77%
Average Trading Volume: 737,042
Technical Sentiment Consensus Rating: Buy
For a thorough assessment of SYNC stock, go to TipRanks’ Stock Analysis page.
